Canaccord Genuity Group Boosts Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $442.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price objective upped by analysts at Canaccord Genuity Group from $436.00 to $442.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “hold” rating on the pharmaceutical company’s stock. Canaccord Genuity Group’s target price points to a potential downside of 6.10% from the stock’s current price.

VRTX has been the topic of several other research reports. Cantor Fitzgerald lifted their price target on Vertex Pharmaceuticals from $590.00 to $595.00 and gave the stock an “overweight” rating in a report on Tuesday. Morgan Stanley upped their price objective on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. Barclays lifted their target price on shares of Vertex Pharmaceuticals from $607.00 to $615.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Truist Financial boosted their target price on shares of Vertex Pharmaceuticals from $542.00 to $560.00 and gave the company a “buy” rating in a report on Monday, July 13th. Finally, Wall Street Zen cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Twenty-two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $560.09.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock opened at $470.72 on Tuesday. Vertex Pharmaceuticals has a one year low of $362.50 and a one year high of $533.67. The company has a market cap of $119.47 billion, a price-to-earnings ratio of 27.92, a PEG ratio of 2.15 and a beta of 0.30. The business’s 50 day moving average price is $471.34 and its 200 day moving average price is $460.44.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01). The company had revenue of $3.33 billion for the quarter, compared to analyst estimates of $3.23 billion. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The business’s quarterly revenue was up 12.5% on a year-over-year basis. During the same period last year, the firm posted $4.52 EPS. On average, analysts predict that Vertex Pharmaceuticals will post 17.01 EPS for the current fiscal year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 1,500 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $524.99, for a total transaction of $787,485.00. Following the transaction, the executive vice president directly owned 45,321 shares in the company, valued at $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Duncan Mckechnie sold 1,541 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total value of $799,779.00. Following the transaction, the executive vice president owned 11,001 shares of the company’s stock, valued at approximately $5,709,519. This represents a 12.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 17,452 shares of company stock valued at $8,103,997 over the last quarter. 0.20% of the stock is owned by company insiders.

Institutional Trading of Vertex Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Brighton Jones LLC boosted its position in Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after buying an additional 579 shares during the period. Gamco Investors INC. ET AL acquired a new position in Vertex Pharmaceuticals during the 2nd quarter worth $228,000. NewEdge Advisors LLC increased its holdings in Vertex Pharmaceuticals by 9.0% during the 2nd quarter. NewEdge Advisors LLC now owns 11,929 shares of the pharmaceutical company’s stock worth $5,311,000 after purchasing an additional 986 shares during the period. ICW Investment Advisors LLC raised its position in Vertex Pharmaceuticals by 5.0% in the 2nd quarter. ICW Investment Advisors LLC now owns 604 shares of the pharmaceutical company’s stock valued at $269,000 after purchasing an additional 29 shares in the last quarter. Finally, Diversify Advisory Services LLC grew its position in shares of Vertex Pharmaceuticals by 26.3% during the second quarter. Diversify Advisory Services LLC now owns 7,291 shares of the pharmaceutical company’s stock worth $3,246,000 after buying an additional 1,518 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue rose 12.5% year over year to $3.33 billion, topping analysts’ $3.23 billion estimate. Growth was supported by strong demand for Vertex’s cystic fibrosis medicines, as well as continued contributions from sickle cell disease, beta thalassemia and acute pain products. Vertex raises annual revenue forecast on cystic fibrosis drugs strength
• Positive Sentiment: Vertex raised its 2026 revenue outlook to $13.1 billion-$13.2 billion, implying a $13.15 billion midpoint slightly above the $13.0 billion analyst consensus. The higher forecast reflects sustained cystic fibrosis sales momentum. Vertex Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance
• Positive Sentiment: The pending acquisition of Crinetics would expand Vertex into rare endocrine diseases through Paltusotine and create a fifth commercial pillar, potentially diversifying growth beyond cystic fibrosis. Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Adjusted EPS increased to $4.73 from $4.52 a year earlier and was essentially in line with the $4.74 consensus in some reports, while other estimates showed a slightly wider miss at $4.79. This modest earnings shortfall limited the positive reaction to the revenue beat. Vertex Pharmaceuticals Q2 2026 Earnings Call Transcript
• Negative Sentiment: Investors appear concerned about the approximately $10 billion Crinetics purchase, including its execution risk and the need to absorb a sizable acquisition while Vertex continues investing in its pipeline. Those concerns, combined with the EPS miss, contributed to the stock’s decline despite stronger sales guidance. Vertex Raises 2026 Guidance, But Shares Dip For One Key Reason

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.